HTLV-II AMONG INJECTING DRUG-USERS IN STOCKHOLM

134 injecting drug users (IDUs) treated at the Department of Infection s Diseases of Roslagstull Hospital, Stockholm, were tested for antibod ies to human T-lymphotropic virus, types I and II, by means of 2 HTLV- I/-II peptide-based enzyme immunoassays (EIAs), followed by a whole-vi rus EIA. Positive EIA reactions were checked and typed by electrophore tic immunoblotting with native HTLV-I and recombinant HTLV-I and -II p roteins. 10 IDUs were diagnosed as HTLV-II seropositive. All 10 were o f Scandinavian descent. Thus, like HIV-1, HTLV-Il infection has entere d the injecting drug user population in Stockholm.